Used primarily in research settings as a selective inhibitor of mitochondrial complex I, this compound is investigated for its potential anticancer properties. It targets tumor cell metabolism by disrupting oxidative phosphorylation, which can lead to reduced cancer cell proliferation, especially in hypoxic environments commonly found in solid tumors. Studies explore its efficacy in melanoma and other cancers where metabolic adaptation plays a key role in tumor progression. Its application remains confined to preclinical research, aiding the understanding of cancer bioenergetics and the development of metabolism-targeted therapies.